CHEIの横紋筋融解症リスク比較 https://t.co/xrYUZ5teoz
What is your approach to creatine kinase elevation? https://t.co/SmBEtqfcxP What about asymptomatic CK elevation? https://t.co/p6wn4ujv1O Don't forget the 4 other muscle enzymes that may also be elevated are AST, ALT, lactate dehydrogenase, and aldolase.
What about meds? h/o hyperlipidemia and on a statin ✅, he has Alzheimer's as well. Is there a connection? There is a risk of rhabdomyolysis with donepezil https://t.co/p6wn4ujv1O Initiating donepezil is assoc w/ a higher 30-day risk of rhabdomyolysis .
Continue pharmacovigilance for choolinesterase inhibitors: Risk of Rhabdomyolysis With Donepezil Compared With Rivastigmine or Galantamine: A Population-Based Cohort Study https://t.co/AiGXMi32Ac
RT @TripPrimaryCare: New2Trip: Risk of rhabdomyolysis w/ donepezil compared w/ rivastigmine or galantamine: population-based cohort study h…
New2Trip: Risk of rhabdomyolysis w/ donepezil compared w/ rivastigmine or galantamine: population-based cohort study https://t.co/0yvROV8JZt
#総合内科 #総合診療 #横紋筋融解症 #認知症 #CMAL #ドネペジル 認知症治療薬の効果が乏しい時に家族と中止について話し合うことはありましたが、横紋筋融解症を起こすんですね。 https://t.co/WMLSu4Z304 https://t.co/nIcHpARXsG
RT @TripPrimaryCare: New2Trip: Risk of rhabdomyolysis w/ donepezil compared w/ rivastigmine or galantamine: population-based cohort study h…
New2Trip: Risk of rhabdomyolysis w/ donepezil compared w/ rivastigmine or galantamine: population-based cohort study https://t.co/0yvROV8JZt
New2Trip: Risk of rhabdomyolysis w/ donepezil compared w/ rivastigmine or galantamine: population-based cohort study https://t.co/ozhY17ATll
New2Trip: Risk of rhabdomyolysis w/ donepezil compared w/ rivastigmine or galantamine: population-based cohort study https://t.co/0yvROV8JZt
New2Trip: Risk of rhabdomyolysis w/ donepezil compared w/ rivastigmine or galantamine: population-based cohort study https://t.co/0yvROV8JZt
New2Trip: Risk of rhabdomyolysis w/ donepezil compared w/ rivastigmine or galantamine: population-based cohort study https://t.co/ozhY17ATll
New2Trip: Risk of rhabdomyolysis w/ donepezil compared w/ rivastigmine or galantamine: population-based cohort study https://t.co/0yvROV8JZt
New2Trip: Risk of rhabdomyolysis w/ donepezil compared w/ rivastigmine or galantamine: population-based cohort study https://t.co/0yvROVqkR1
New2Trip: Risk of rhabdomyolysis w/ donepezil compared w/ rivastigmine or galantamine: population-based cohort study https://t.co/0yvROV8JZt
New2Trip: Risk of rhabdomyolysis w/ donepezil compared w/ rivastigmine or galantamine: population-based cohort study https://t.co/0yvROV8JZt
New2Trip: Risk of rhabdomyolysis w/ donepezil compared w/ rivastigmine or galantamine: population-based cohort study https://t.co/0yvROV8JZt
RT @BITNavarra: Donepezilo. Mayor riesgo de rabdomiolisis que rivastigmina y galantamina https://t.co/ejaOnWZm9h
New2Trip: Risk of rhabdomyolysis w/ donepezil compared w/ rivastigmine or galantamine: population-based cohort study https://t.co/0yvROV8JZt
RT @RevistaMFSamfyc: Riesgo de rabdomiolisis con el Donepezilo comparado con Rivastigmina o Galantamina: estudio de cohorte poblacional htt…
RT @GavinGiovannoni: #NeuroSpeak An important paper! Risk of rhabdomyolysis with donepezil compared with rivastigmine or galantamine: a pop…
RT @Lodonah: هنا رابط دراسة التمارين القلبية https://t.co/edSRjU3ypm و هنا رابط بحث الدواء https://t.co/SUBbiYzQ91 الحساب برعاية المركز ا…
Donepezil use linked to higher risk of rhabdomyolysis via @CMAJ https://t.co/cTNTRY8tnF https://t.co/pbILyqJvCu
RT @yamotoshinikana: 認知症患者のドネペジルの使用は、リバスチグミンまたはガランタミンと比較して、横紋筋融解症による入院リスクが上昇した。 カナダのコホート研究。 https://t.co/goW2QbzE8j PMID:31527187
Risk of rhabdomyolysis with donepezil compared with rivastigmine or galantamine: a population-based cohort study. - PubMed - NCBI https://t.co/N8yQi2JSNS
RT @yamotoshinikana: 認知症患者のドネペジルの使用は、リバスチグミンまたはガランタミンと比較して、横紋筋融解症による入院リスクが上昇した。 カナダのコホート研究。 https://t.co/goW2QbzE8j PMID:31527187
RT @yamotoshinikana: 認知症患者のドネペジルの使用は、リバスチグミンまたはガランタミンと比較して、横紋筋融解症による入院リスクが上昇した。 カナダのコホート研究。 https://t.co/goW2QbzE8j PMID:31527187
身内が服用しており、気をつけて観察します。ありがとうございます。 https://t.co/NIhIPyyErh
RT @yamotoshinikana: 認知症患者のドネペジルの使用は、リバスチグミンまたはガランタミンと比較して、横紋筋融解症による入院リスクが上昇した。 カナダのコホート研究。 https://t.co/goW2QbzE8j PMID:31527187
認知症患者のドネペジルの使用は、リバスチグミンまたはガランタミンと比較して、横紋筋融解症による入院リスクが上昇した。 カナダのコホート研究。 https://t.co/goW2QbzE8j PMID:31527187
RT @Lodonah: هنا رابط دراسة التمارين القلبية https://t.co/edSRjU3ypm و هنا رابط بحث الدواء https://t.co/SUBbiYzQ91 الحساب برعاية المركز ا…
هنا رابط دراسة التمارين القلبية https://t.co/edSRjU3ypm و هنا رابط بحث الدواء https://t.co/SUBbiYzQ91 الحساب برعاية المركز الوطني لتعزيز الصحة النفسية @NCMH_SA #PsychDDx_Dementia #PsychDDx_Neuropsychiatry
Riesgo de rabdomiolisis con el Donepezilo comparado con Rivastigmina o Galantamina: estudio de cohorte poblacional https://t.co/GUDsdE797N PMID 31527187
RT @inmmorrop: A tenerlo muy en cuenta https://t.co/BiNB9y8pzt
RT @Sefap_FAP: Comparativa del riesgo de rabdomiolisis del donezepilo frente a rivastigmina o galantamina. via @FarmaMadridAP https://t.co…
RT @Sefap_FAP: Comparativa del riesgo de rabdomiolisis del donezepilo frente a rivastigmina o galantamina. via @FarmaMadridAP https://t.co…
RT @BITNavarra: Donepezilo. Mayor riesgo de rabdomiolisis que rivastigmina y galantamina https://t.co/ejaOnWZm9h
RT @Sefap_FAP: Comparativa del riesgo de rabdomiolisis del donezepilo frente a rivastigmina o galantamina. via @FarmaMadridAP https://t.co…
RT @BITNavarra: Donepezilo. Mayor riesgo de rabdomiolisis que rivastigmina y galantamina https://t.co/ejaOnWZm9h
RT @Sefap_FAP: Comparativa del riesgo de rabdomiolisis del donezepilo frente a rivastigmina o galantamina. via @FarmaMadridAP https://t.co…
RT @BITNavarra: Donepezilo. Mayor riesgo de rabdomiolisis que rivastigmina y galantamina https://t.co/ejaOnWZm9h
RT @BITNavarra: Donepezilo. Mayor riesgo de rabdomiolisis que rivastigmina y galantamina https://t.co/ejaOnWZm9h
Comparativa del riesgo de rabdomiolisis del donezepilo frente a rivastigmina o galantamina. via @FarmaMadridAP
RT @inmmorrop: A tenerlo muy en cuenta https://t.co/BiNB9y8pzt
RT @inmmorrop: A tenerlo muy en cuenta https://t.co/BiNB9y8pzt
RT @inmmorrop: A tenerlo muy en cuenta https://t.co/BiNB9y8pzt
RT @inmmorrop: A tenerlo muy en cuenta https://t.co/BiNB9y8pzt
RT @BITNavarra: Donepezilo. Mayor riesgo de rabdomiolisis que rivastigmina y galantamina https://t.co/ejaOnWZm9h
RT @inmmorrop: A tenerlo muy en cuenta https://t.co/BiNB9y8pzt
A tenerlo muy en cuenta
RT @BITNavarra: Donepezilo. Mayor riesgo de rabdomiolisis que rivastigmina y galantamina https://t.co/ejaOnWZm9h
Donepezilo. Mayor riesgo de rabdomiolisis que rivastigmina y galantamina https://t.co/ejaOnWZm9h
RT @GavinGiovannoni: #NeuroSpeak An important paper! Risk of rhabdomyolysis with donepezil compared with rivastigmine or galantamine: a pop…
#NeuroSpeak An important paper! Risk of rhabdomyolysis with donepezil compared with rivastigmine or galantamine: a population-based cohort study https://t.co/Om8MRbhEdb https://t.co/Cb62ZkF2NC
よく分からないけど、軽症で済むことが多い。
【コホート研究】66歳以上の新規処方患者において、ドネペジルは、リバスチグミンやガランタミンと比較して、横紋筋融解症による入院のより高いリスクと関連した(ドネペジル使用後に入院した患者の大部分は重症ではなく、緊急透析や人工呼吸器導入には至らなかった)。 https://t.co/aENzAA0bFd
Iniciar donepezilo estaría asociado con un mayor riesgo a 30 días de ingreso al hospital con rabdomiólisis comparados con iniciar rivastigmina o galantamina https://t.co/aR8u6v4bY5
Risk of #rhabdomyolysis with #donepezil compared with rivastigmine or galantamine: a population-based cohort study https://t.co/07mA2gOecn
(CMAJ) Comparativa del riesgo de rabdomiolisis del donezepilo frente a rivastigmina o galantamina. https://t.co/vKjFtImma9
ドネペジルの使用はリバスチグミンやガランタミンと比較して横紋筋融解による入院のリスク上昇と関連する。CMAJ. 2019;191:E1018. PMID: 31527187 https://t.co/mZjqetTPeX
The risk is higher with donepezil than with other drugs in the class, but the overall risk is low. https://t.co/H5UbEZbgH7
Risk of rhabdomyolysis with donepezil compared with rivastigmine or galantamine: a population-based cohort study. CMAJ #Alzheimers https://t.co/P50OtnyYtk
Risk of rhabdomyolysis with donepezil compared with rivastigmine or galantamine: a population-based cohort study https://t.co/fajLOZrgzn
The short-term risk for #rhabdomyolysis was >twice in adults receiving #donepezil (#Aricept) vs #rivastigmine (Exelon) or #galantamine (Razadyne). #dementia https://t.co/zlwSJQ7b23
Risk of rhabdomyolysis with donepezil compared with rivastigmine or galantamine: a population-based cohort study | CMAJ https://t.co/opHoWimMmm
cohort study: Donepezil was associated with a higher risk of hospital admission with rhabdomyolysis compared with rivastigmine or galantamine (OR=2.21; 1.52–3.22). Most hospital admissions with rhabdomyolysis after donepezil use were not severe https://t.c
RT @GERAScentre: New GERAS open-access publication in @CMAJ_Open shows increase risk of hospitalization in patients using #donepezil a medi…
RT @GERAScentre: New GERAS open-access publication in @CMAJ_Open shows increase risk of hospitalization in patients using #donepezil a medi…
RT @CMAJ: Commonly used drug for Alzheimer disease doubles risk of hospitalization, new study in CMAJ finds: https://t.co/e6KuCkVc0w @ICE…
RT @GERAScentre: New GERAS open-access publication in @CMAJ_Open shows increase risk of hospitalization in patients using #donepezil a medi…
RT @ICESOntario: Patients with #dementia newly started on cholinesterase inhibitor donepezil at doubled 30-day risk of hospital admission f…
RT @GERAScentre: New GERAS open-access publication in @CMAJ_Open shows increase risk of hospitalization in patients using #donepezil a medi…
220,000 人超患者のデータで、#Aricept の横紋筋融解による入院のオッズがrivastigmine・ galantamineの 2.21倍であることを報告。但し、スタチンでも起こるレベル、と:McMaster。 https://t.co/gGg9WCJb2z
RT @GERAScentre: New GERAS open-access publication in @CMAJ_Open shows increase risk of hospitalization in patients using #donepezil a medi…
RT @GERAScentre: New GERAS open-access publication in @CMAJ_Open shows increase risk of hospitalization in patients using #donepezil a medi…
RT @GERAScentre: New GERAS open-access publication in @CMAJ_Open shows increase risk of hospitalization in patients using #donepezil a medi…
New GERAS open-access publication in @CMAJ_Open shows increase risk of hospitalization in patients using #donepezil a medication used for Alzheimer’s disease & other dementias. Great work Dr. Jamie Fleet (@Fleet_J) & team! 🏨🧠 Read the full paper —
RT @CMAJ: Commonly used drug for Alzheimer disease doubles risk of hospitalization, new study in CMAJ finds: https://t.co/e6KuCkVc0w @ICE…
RT @CMAJ: Commonly used drug for Alzheimer disease doubles risk of hospitalization, new study in CMAJ finds: https://t.co/e6KuCkVc0w @ICE…
RT @CMAJ: Commonly used drug for Alzheimer disease doubles risk of hospitalization, new study in CMAJ finds: https://t.co/e6KuCkVc0w @ICE…
RT @CMAJ: Commonly used drug for Alzheimer disease doubles risk of hospitalization, new study in CMAJ finds: https://t.co/e6KuCkVc0w @ICE…
RT @CMAJ: Commonly used drug for Alzheimer disease doubles risk of hospitalization, new study in CMAJ finds: https://t.co/e6KuCkVc0w @ICE…
RT @CMAJ: Commonly used drug for Alzheimer disease doubles risk of hospitalization, new study in CMAJ finds: https://t.co/e6KuCkVc0w @ICE…
RT @CMAJ: Commonly used drug for Alzheimer disease doubles risk of hospitalization, new study in CMAJ finds: https://t.co/e6KuCkVc0w @ICE…
Commonly used drug for Alzheimer disease doubles risk of hospitalization, new study in CMAJ finds: https://t.co/e6KuCkVc0w @ICESOntario @Fleet_J #AlzheimersDisease #dementia https://t.co/U393SDlVYS
Donepezil and risk of hospitalization paper out in @CMAJ today
#Aricept, a drug commonly used to manage cognitive declines in #Alzheimer’s patients, may be associated with a higher risk of hospitalizations for a type of muscle injury — a known side effect of these drugs.https://t.co/Wa94Vyug10
RT @ICESOntario: Patients with #dementia newly started on cholinesterase inhibitor donepezil at doubled 30-day risk of hospital admission f…
RT @ICESOntario: Patients with #dementia newly started on cholinesterase inhibitor donepezil at doubled 30-day risk of hospital admission f…
Patients with #dementia newly started on cholinesterase inhibitor donepezil at doubled 30-day risk of hospital admission for rhabdomyolysis (vs rivastigmine or galantamine), but absolute risk remains very low: @ICESOntario study in @CMAJ #drugsafety https:
Risk of rhabdomyolysis with donepezil compared with rivastigmine or galantamine: a population-based cohort study | CMAJ https://t.co/cyOWqS31V4
Risk of rhabdomyolysis with donepezil compared with rivastigmine or galantamine: a population-based cohort study https://t.co/98K6R2nqyI
Increased muscle cramps found in RCTs of donepezil do translate in increased, but still rare, cases of rhabdomyolysis https://t.co/OkJE63Dq0f
https://t.co/1dNS9zBJ40 @CMAJ reports risk of rhabdomyolysis with cholinesterase inhibitors, small but statistically more significant risk with donepezil than galantamine and rivastigmine.
Risk of rhabdomyolysis with donepezil compared with rivastigmine or galantamine: https://t.co/EVZKq5wroQ